Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Revenue Ownership Financials Chart Transcripts

Previous Close

$0.63

52W Range

$0.48 - $6.18

50D Avg

$0.63

200D Avg

$0.92

Market Cap

$3.16M

Avg Vol (3M)

$2.66M

Beta

1.89

Div Yield

-

QNRX Company Profile

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

4

IPO Date

Aug 01, 2016

Website

QNRX Performance

QNRX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-9.35M	$-8.85M	$-20.37M
Net Income	$-8.66M	$-9.28M	$-8.52M
EBITDA	$-8.69B	$-8.74M	$-20.27M
Basic EPS	$-9.62	$-45.96	$-323.63
Diluted EPS	$-9.62	$-45.96	$-323.63

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 14, 24 | 12:57 PM

Q3 23Nov 09, 23 | 10:51 AM

Q2 23Aug 07, 23 | 1:24 AM

Peer Comparison

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
BWV	Onconetix, Inc.
PXMD	PaxMedica, Inc. Common Stock
REVB	Revelation Biosciences, Inc.
HILS	Tharimmune, Inc.
VRAX	Virax Biolabs Group Limited
ALLR	Allarity Therapeutics, Inc.
NRBO	NeuroBo Pharmaceuticals, Inc.
UNCY	Unicycive Therapeutics, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.